☆ 4.1 Review

Ustekinumab to treat Crohn's disease

GASTROENTEROLOGIA Y HEPATOLOGIA (2017)

Journal

GASTROENTEROLOGIA Y HEPATOLOGIA

Volume 40, Issue 10, Pages 688-698

Publisher

ELSEVIER DOYMA SL

DOI: 10.1016/j.gastrohep.2017.08.006

Keywords

Crohn's disease; Anti-TNF; Ustekinumab

Categories

Gastroenterology & Hepatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Ustekinumab is a monoclonal antibody directed against the p40 subunit, which is part of interteukins IL-12 and IL-23. The efficacy of ustekinumab versus placebo in terms of clinical response and remission of induction has been shown in phase 3 clinical trials. When used as subcutaneous maintenance therapy, the therapeutic benefit of ustekinumab over placebo has been confirmed in both clinical response and remission in patients who have responded clinically to induction therapy. In addition, ustekinumab has demonstrated an improvement in mucosal healing parameters. The safety profile of the drug has been good, with low infection rates (without reactivation of tuberculosis) and absence of tumour reporting. The development of drug immunogenicity appears to be rare. In summary, ustekinumab is a promising treatment option in patients with Crohn's disease, as an alternative to anti-TNF drugs. (C) 2017 Elsevier Espana, S.L.U. All rights reserved.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Gastroenterology & Hepatology

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease

Carl Eriksson, Jonas Soderling, Sara Karlqvist, Gabriella Broms, Asa H. Everhov, Daniel F. Bergemalm, Jonas Ludvigsson, Ola Olen, Jonas Halfvarson

Summary: This study aimed to compare and evaluate the comparative effectiveness and safety of ustekinumab and anti-TNF treatment in patients with Crohn's disease who failed first-line anti-TNF therapy. The results showed no significant differences in effectiveness or safety between ustekinumab and anti-TNF treatment in patients with prior exposure to anti-TNF therapy for Crohn's disease.

DIGESTIVE DISEASES AND SCIENCES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers

Pauline Riviere, Caitlyn Kanters, Gauthier Pellet, Alexander Ni, Marianne Hupe, Nesrine Aboulhamid, Florian Poullenot, Alain Bitton, Frank Zerbib, Peter L. Lakatos, Waqqas Afif, David Laharie, Talat Bessissow

Summary: This study aimed to compare the efficacy of anti-tumor necrosis factor agents and ustekinumab in patients with Crohn's disease. The results showed that anti-tumor necrosis factor agents as first-line biological therapy were associated with higher response rates at 3 months compared to ustekinumab.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Medicine, General & Internal

Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort Study

Ahmad Albshesh, Lian Bannon, Tali Sharar Fischler, Marie Truyens, Stephan R. R. Vavricka, Katja Tepes, Daniela Pugliese, Edoardo V. V. Savarino, Eran Zittan, David Drobne, Xavier Roblin, Ariella Bar-Gil Shitrit, Alessandro Armuzzi, Triana Lobaton, Nitsan Maharshak, Henit Yanai, Shomron Ben-Horin, Uri Kopylov

Summary: The effectiveness of anti-TNF or ustekinumab as a second-line biologic after vedolizumab failure in patients with Crohn's disease was investigated. The results showed that there was no significant difference in the clinical response, remission rate, and discontinuation rate between the use of anti-TNF and ustekinumab as a second-line therapy.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Anti-TNFα treatment in Crohn's disease: Impact on hepatic steatosis, gut-derived hormones and metabolic status

Paul Manka, Svenja Sydor, Nishikant Wase, Jan Best, Malte Brandenburg, Annika Hellbeck, Julia Schanzer, Ramiro Vilchez-Vargas, Alexander Link, Anja Figge, Andreas Jahnert, Ulrike von Arnim, Jason D. Coombes, Francisco-Javier Cubero, Alisan Kahraman, Moon-Sung Kim, Julia Kalsch, Sonja Kinner, Klaas-Nico Faber, Han Moshage, Guido Gerken, Wing-Kin Syn, Scott L. Friedman, Ali Canbay, Lars P. Bechmann

Summary: In this study, the potential relationship between anti-TNF treatment and hepatic steatosis in Crohn's disease was analyzed. Patients on anti-TNF treatment showed reduced hepatic steatosis, higher serum FGF19 levels, and lower levels of neutral lipids such as triglycerides. The abundance of Firmicutes, bacteria involved in bile acid metabolism and FGF19 regulation, was associated with triglyceride levels and showed group-specific alterations.

LIVER INTERNATIONAL (2021)

Add to Collection

Article Immunology

Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease

Liliana Lykowska-Szuber, Michal Walczak, Marzena Skrzypczak-Zielinska, Joanna Suszynska-Zajczyk, Kamila Stawczyk-Eder, Katarzyna Waszak, Piotr Eder, Anna Wozniak, Iwona Krela-Kazmierczak, Ryszard Slomski, Agnieszka Dobrowolska

Summary: Crohn's disease patients who do not respond to anti-TNF therapy may have alterations in the expression levels of specific genes, particularly TNFRSF1B, FCGR3A, and IL1B. This can be predicted by functional analysis in colon biopsies and cell culture models.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study

Rayer Cassandra, Maria Nachury, Bourreille Arnaud, Roblin Xavier, Peyrin-Biroulet Laurent, Viennot Stephanie, Flamant Mathurin, Laharie David, Caron Benedicte, Dewitte Marie, Siproudhis Laurent, Fumery Mathurin, Bouguen Guillaume

Summary: This study compared the efficacy of biologics in patients with Crohn's disease who failed the first anti-TNF agent. The results showed that VDZ, UST, and a second anti-TNF agent exhibited similar efficacy in the short term, but UST had shorter drug maintenance.

BMC GASTROENTEROLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Ustekinumab trough levels in children with Crohn's disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use

Marleen Bouhuys, Paola Mian, Patrick F. van Rheenen

Summary: Ustekinumab shows efficacy in pediatric Crohn's disease, but there is limited research on dosing, target trough levels, and therapeutic drug monitoring. Gradually escalating the dose may improve the response to ustekinumab. Further studies are needed to determine the long-term efficacy and optimal trough levels in children.

FRONTIERS IN PHARMACOLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary

Lorant Gonczi, Kata Szanto, Klaudia Farkas, Tamas Molnar, Tamas Szamosi, Eszter Schafer, Petra A. Golovics, Laszlo Barkai, Livia Lontai, Barbara Lovasz, Mark Juhasz, Arpad Patai, Krisztina Sarang, Aron Vincze, Patricia Sarlos, Alexandra Farkas, Zsolt Dubravcsik, Tamas G. Toth, Pal Miheller, Akos Ilias, Peter L. Lakatos

Summary: The clinical efficacy, drug sustainability, dose intensification, and therapeutic drug monitoring of ustekinumab therapy in patients with Crohn's disease were evaluated in this prospective, nationwide, multicenter cohort study. The study found that ustekinumab showed favorable drug sustainability and clinical efficacy in patients with severe disease phenotype and previous anti-tumor necrosis factor failure. However, frequent dose intensification was required.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn's Disease

Albert Boronat-Toscano, Diandra Monfort-Ferre, Margarita Menacho, Aleidis Caro, Ramon Bosch, Beatriz Espina, Francisco Algaba-Chueca, Alfonso Saera-Vila, Alicia Moline, Marc Marti, Eloy Espin, Monica Millan, Carolina Serena

Summary: This study found that anti-TNF therapy can restore the morphology of creeping fat in patients with CD, suppress immune cell infiltration, and improve inflammation in adipose tissue.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Review Gastroenterology & Hepatology

Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies

Renske W. M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Maria J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamas Molnar, Kata Szanto, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D'Haens, Annemarie C. de Vries

Summary: This study validated and updated a prediction model for relapse risk stratification in Crohn's disease (CD) patients after anti-TNF therapy cessation. The updated model, including clinical symptoms at cessation, younger age at diagnosis, no concomitant immunosuppressants, smoking, second-line anti-TNF therapy, upper gastrointestinal tract involvement, adalimumab, age at cessation, C-reactive protein, and longer disease duration, showed a reasonable discriminative ability (C-statistic, 0.59). Adding fecal calprotectin improved the model's discriminative ability (C-statistic, 0.63). Further validation is necessary, but this model may be useful in guiding clinical decisions on anti-TNF therapy cessation in CD patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy

Luc Manlay, Gilles Boschetti, Bruno Pereira, Bernard Flourie, Michel Dapoigny, Maud Reymond, Elisa Sollelis, Claire Gay, Mathilde Boube, Anthony Buisson, Stephane Nancey

Summary: The study compared the short- and long-term effectiveness of vedolizumab and ustekinumab in Crohn's disease patients who had previously failed response to anti-TNF agents. The results showed that ustekinumab was more effective than vedolizumab in achieving corticosteroid-free clinical remission.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease

Kira L. L. Newman, Laura A. A. Johnson, Ryan W. W. Stidham, Peter D. R. Higgins

Summary: This study evaluated the response to ustekinumab (UST) and vedolizumab (VDZ) in patients with fistulizing Crohn's disease (CD). The findings suggest that UST has better clinical utility than VDZ based on lower rates of discontinuation, highlighting the importance of further research on the treatment of fistulizing CD.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn's Disease: A Study Based on the Korean National Database

Gi Hyeon Seo, Sung Hoon Jung

Summary: The efficacy of ustekinumab was compared with anti-TNF inhibitors in patients with moderate to severe Crohn's disease. Data analysis of Korean National Health Insurance Service showed that one-year persistence rate of ustekinumab was significantly higher than that of anti-TNF inhibitors.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Whole Blood DNA Methylation Changes Are Associated with Anti-TNF Drug Concentration in Patients with Crohn's Disease

Simeng Lin, Eilis Hannon, Mark Reppell, Jeffrey F. Waring, Nizar Smaoui, Valerie Pivorunas, Heath Guay, Neil Chanchlani, Claire Bewshea, Benjamin Y. H. Bai, Nicholas A. Kennedy, James R. Goodhand, Jonathan Mill, Tariq Ahmad, PANTS Consortium

Summary: The study identified epigenetic biomarkers in whole blood at baseline that can predict anti-TNF drug concentrations at week 14, which may help identify patients who could benefit from dose optimization at the beginning of anti-TNF therapy.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease

Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch

Summary: This post hoc analysis suggests that infliximab and ustekinumab have similar efficacy and speed of onset in biologic-naive patients with CD.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU

Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Francisco Mesonero, Francisco Javier Garcia-Alonso, Maria Jose Casanova, Margarita Fernandez-de la Varga, Fiorella Canete, Luisa de Castro, Ana Gutierrez, Beatriz Sicilia, Victoria Cano, Olga Merino, Ruth de Francisco, Irene Gonzalez-Partida, Gerard Suris, Leyanira Torrealba, Rocio Ferreiro-Iglesias, Beatriz Castro, Lucia Marquez, Ana Sobrino, Ainara Elorza, Xavier Calvet, Pilar Varela, Raquel Vicente, Luis Bujanda, Laura Lario, Noemi Mancenido, Mariana F. Garcia-Sepulcre, Eva Iglesias, Cristina Rodriguez, Marta Piqueras, Juan Angel Ferrer Rosique, Alfredo J. Lucendo, Olga Benitez, Melody Garcia, David Olivares, Carlos Gonzalez-Munoza, Beatriz Lopez-Cauce, Victor Jair Morales Alvarado, Katerina Spicakova, Alicia Brotons, Fernando Bermejo, Pedro Almela, Nahia Ispizua, Pau Gilabert, Carlos Tardillo, Fernando Munoz, Pablo Navarro, Rosa Eva Madrigal Dominguez, Pau Sendra, Esther Hinojosa, Empar Sainz, Maria Dolores Martin-Arranz, Daniel Carpio, Elena Ricart, Berta Caballol, Laura Nunez, Jesus Barrio, Javier P. Gisbert, Marisa Iborra, Margalida Calafat, Vicent Hernandez, Roser Munoz Perez, Jose Luis Cabriada, Eugeni Domenech, Iago Rodriguez-Lago

Summary: This study evaluated the effectiveness of biologic agents in Crohn's disease complicated with internal fistulizing disease. It found that biologic therapy is beneficial for approximately three-quarters of patients, achieving a fistula closure rate of 24%, but around one-third of patients still require surgery. Patient- and lesion-related factors can identify patients who will obtain more benefit from these drugs.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management

Luigi Gatta, Olga P. Nyssen, Giulia Fiorini, Ilaria Maria Saracino, Matteo Pavoni, Marco Romano, Antonietta Gerarda Gravina, Lucia Granata, Rinaldo Pellicano, Antonio Gasbarrini, Alfredo Di Leo, Giuseppe Losurdo, Francesco Franceschi, Gerardo Nardone, Alba Rocco, Maria Pina Dore, Fabio Farinati, Matteo Ghisa, Massimo Bellini, John Holton, Ignasi Puig, Dino Vaira, Claudio Borghi, Francis Megraud, Colm O'Morain, Javier P. Gisbert

Summary: This study evaluated the effectiveness and safety of empirical first- and second-line treatments for Helicobacter pylori patients. Only quadruple therapies lasting at least 10 days achieved over 90% eradication rates, and high-dose PPI twice daily improved the effectiveness of some treatments.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

Add to Collection

Article Oncology

Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry Study

Ivan Guerra, Luis Bujanda, Miriam Manosa, Isabel Perez-Martinez, Maria Jose Casanova, Luisa de la Pena, Marina de Benito, Montserrat Rivero, Pilar Varela, Lorena Bernal, Ana Carolina Franco, Yolanda Ber, Marta Piqueras, Carlos Tardillo, Angel Ponferrada, Sonsoles Olivares, Alfredo J. J. Lucendo, Pau Gilabert, Monica Sierra Ausin, Maria Bellart, Amaia Herrarte, Margalida Calafat, Ruth de Francisco, Javier P. Gisbert, Jordi Guardiola, Eugeni Domenech, Fernando Bermejo

Summary: An increased risk of lymphoma has been found in patients with inflammatory bowel disease (IBD). This study aimed to analyze the management and evolution of lymphomas in IBD patients. The majority of IBD patients had been treated with thiopurines and/or anti-TNF agents before lymphoma diagnosis, and these treatments did not impact the relapse and mortality of lymphoma.

CANCERS (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis

Montse Baldan-Martin, Maria Chaparro, Javier P. Gisbert

Summary: Inflammatory bowel diseases (IBDs) are chronic and inflammatory conditions affecting the gastrointestinal tract. Despite endoscopy being the gold standard test for assessing IBD, it is invasive and uncomfortable for patients. Therefore, non-invasive biomarkers for IBD diagnosis are urgently needed. This review summarizes proteomics and metabolomics studies in animals and humans, identifying urinary biomarkers for IBD diagnosis. Large-scale multi-omics studies with collaboration between clinicians, researchers, and industry are necessary for the development of sensitive and specific diagnostic biomarkers for personalized medicine.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Adalimumab Clearance, Rather Than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically

Emily K. Wright, Maria Chaparro, Paolo Gionchetti, Amy L. Hamilton, Julien Schulberg, Javier P. Gisbert, Maria Chiara Valerii, Fernando Rizzello, Peter De Cruz, John C. Panetta, Annelie Everts-van der Wind, Michael A. Kamm, Thierry Dervieux

Summary: This study found that adalimumab drug clearance is a critical factor in determining the therapeutic outcome of Crohn's disease patients. Patients with lower drug clearance showed better endoscopic remission, while drug concentration did not significantly differ between patients in remission and those with recurrence. Sustained clinical remission based on C-reactive protein and lower faecal calprotectin levels were generally associated with lower clearance and higher drug concentration.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Review Gastroenterology & Hepatology

De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review

Javier P. Gisbert, Maria Chaparro

Summary: The de-escalation of biologic therapy in inflammatory bowel disease (IBD) carries risks and uncertainties and should be tailored to individual patients.

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease

Irene Soleto, Cristina Ramirez, Cristina Gomez, Montse Baldan-Martin, Macarena Orejudo, Jorge Mercado, Maria Chaparro, Javier P. Gisbert

Summary: This study reveals that type 2 conventional DCs (cDC2) in patients with inflammatory bowel disease (IBD) exhibit a heightened migratory profile compared to other DC subsets, potentially highlighting new diagnostic biomarkers or immunomodulatory targets for IBD.

BIOMEDICINES (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

HIV infection is associated with a less aggressive phenotype of inflammatory bowel disease. A multicenter study based on the ENEIDA registry

M. Calafat Sard, C. Suria, F. Mesonero, R. de Francisco, C. Yague Caballero, L. de la Pena, A. Hernandez-Camba, A. Marce, B. Gallego, N. Martin-Vicente, M. Rivero, M. Iborra, I. Guerra, M. Carrillo-Palau, L. Madero, B. Burgueno, D. Montfort, G. Torres, M. Teller, J. A. Ferrer Rosique, P. Vega Villaamil, C. Roig, A. Ponferrada, E. Betore Glaria, Y. Zabana, J. P. Gisbert, N. Alcaide, B. Camps, J. Legido, M. Gonzalez Vivo, M. M. Bosca-Watts, I. Perez-Martinez, D. Casas Deza, J. Guardiola, L. Arranz Hernandez, M. Navarro, F. Gomollon, F. Canete, M. Manosa, E. Domenech

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

COMPARATIVE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB VS ANTI-TNFs IN ULCERATIVE COLITIS BIO-NAIVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNFα (EVOLVE-IBERIA STUDY)

F. Casellas Jorda, C. Rodriguez, J. P. Gisbert, S. Bernardo, J. Aparicio, I. Tagarro, F. Munoz

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases

M. Chaparro, D. Acosta, C. Rodriguez, F. Mesonero, M. Vicuna, M. Barreiro-de Acosta, A. Fernandez-Clotet, A. Hernandez Martinez, M. Arroyo, I. Vera, A. Ruiz-Cerulla, B. Sicilia, M. J. Cabello Tapia, C. Munoz Villafranca, J. Castro-Poceiro, J. Martinez Cadilla, M. Sierra-Ausin, M. Vazquez Moron, E. Montil Miguel, F. Bermejo, V. Royo, M. Calafat, C. Gonzalez-Munoza, E. Leo Carnerero, N. Mancenido Marcos, L. Torrealba, H. Alonso-Galan, M. Benitez, Y. Ber Nieto, M. T. Diz-Lois Palomares, M. J. Garcia, J. F. Munoz, E. M. Armesto Gonzalez, X. Calvet, A. Hernandez-Camba, R. E. Madrigal Dominguez, L. Menchen, J. L. Perez Calle, M. Piqueras, J. P. Gisbert

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding

M. Chaparro, M. Garcia Donday, S. Rubio, C. Calvino Suarez, A. Nunez Ortiz, M. Figueira, S. Marin Pedrosa, M. Rivero, A. Fernandez-Clotet, L. Madero, M. T. Diz-Lois Palomares, I. Perez-Martinez, A. Ruiz-Cerulla, M. Arroyo, M. Piqueras, C. Suarez Ferrer, M. Aguas, M. Calvo Moya, I. Guerra, P. Lopez Serrano, J. M. Vazquez Moron, L. Arias Garcia, M. J. Casanova, J. M. Huguet, G. Valldosera Gomis, B. Zuniga de Mora-Figueroa, R. Armesto, P. Martinez Montiel, I. Rodriguez-Lago, P. Sendra Rumbeu, R. Camargo Camero, D. Hervias Cruz, G. Molina Arriero, M. Barreiro-de Acosta, D. Acosta, Y. Brenes, S. Hermida, P. Parra, A. Garre, J. P. Gisbert

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study

P. Sanz Segura, F. Gomollon, S. Garcia Garcia, M. Vela, A. Fernandez-Clotet, R. Munoz, I. Garcia de la Filia, M. Garcia Prada, J. A. Ferrer Rosique, M. J. Garcia, R. de Francisco, L. Arias, J. Barrio, I. Guerra, A. Ponferrada Diaz, J. P. Gisbert, M. Carrillo-Palau, X. Calvet, L. Marquez-Mosquera, B. Gros, F. Canete, D. Monfort, R. E. Madrigal, O. Roncero, V. Laredo, M. Montoro, C. Munoz, B. Lopez-Cauce, R. Lorente, A. Fuentes, P. Vega, D. Martin, J. Nerin de la Puerta, P. Varela, D. Casas-Deza, P. Martinez, R. Pajares, A. J. Lucendo, E. Domenech, S. Garcia-Lopez

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Immunological effects of hepatitis B virus vaccination in inflammatory bowel disease patients

I. Soleto, A. C. Marin, I. Mora, J. R. Villagrasa, M. Baldan-Martin, C. Ramirez, D. Bernardo, M. Chaparro, J. P. Gisbert

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Proteomic characterization of serum extracellular vesicles from newly diagnosed patients with inflammatory bowel disease

I. Soleto, M. Baldan, C. Ramirez, M. Orejudo, S. Garcia, J. Mercado, M. Azkargorta, I. Lloro, L. Ortega Moreno, L. Aldars Garcia, S. Riestra, M. Rivero, A. Gutierrez, I. Rodriguez-Lago, L. Fernandez, D. Ceballos, J. M. Benitez, M. Aguas, I. Baston Rey, F. Bermejo, M. J. Casanova, R. Lorente, Y. Ber, D. Ginard, M. Esteve, F. Elortza, J. P. Gisbert, N. Martin-Cofreces, M. Chaparro

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

Meeting Abstract Gastroenterology & Hepatology

Effects of anti-TNF and anti-interleukins 12 and 23 drugs on circulating dendritic cells migratory capacity in inflammatory bowel disease

I. Soleto, C. Ramirez, C. Gomez, B. Montse, S. Garcia, M. Orejudo, J. Mecado, M. Chaparro, J. P. Gisbert

JOURNAL OF CROHNS & COLITIS (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.